Watson’s Generic Yaz Gets FDA Approval

With FDA hearings set for 12.8.11 on the significantly elevated risk of blood clots associated with #DRSP #DROSPIRENONE containing birth control, FDA has approved another generic form of #YAZ. An FDA funded study, disclosed last month, came to the same conclusion a number of other studies have reached since 2009 - #DRSP (#DROSPIRENONE) containing birth control pills present a higher risk of blood clots to users. FDA noted this risk was nearly 75% or 1.74x in comparison to other pills. Why approve another generic? What do these pills add to the available birth control options to women or girls that choose a hormonal birth control method? The FDA hearings may shed some light on their reasoning, or result in other changes to how, and to who, the pills are promoted, including increased warning.